ViGenCell EBIT per osake

Mitä ViGenCell tekee? ViGenCell, Inc. generates revenue through the development and manufacturing of immuno-cancer cell therapy products and immunosuppressive cell therapy products. The company provides three main platforms: vitier platform for antigen-specific killing T cell treatment, viranger platform for gammadelta T cell gene therapy, and vimedier platform-based technology for myeloid suppressor cell therapy derived from umbilical cord blood. These platforms target diseases such as acute myeloid leukemia (AML) and glioblastoma, with the company focusing on R&D for new drug development in these areas. The primary buyers of ViGenCell's products and platforms are healthcare providers and research institutions specializing in oncology and immunotherapy. The company's focus on advanced cell therapy technologies positions it to serve the growing market for targeted cancer treatments. ViGenCell's platforms are designed to address specific therapeutic needs, particularly in blood cancers and brain tumors, leveraging their proprietary cell therapy approaches. ViGenCell's business model centers on the commercialization of its proprietary cell therapy platforms. The company develops and manufactures its own cell therapy products, with the vitier, viranger, and vimedier platforms forming the core of its product offerings. These platforms are applied in the treatment of acute myeloid leukemia (AML) and glioblastoma, targeting both the oncology and immunotherapy segments of the healthcare market. ViGenCell on yksi Eurpooliin suosituimmista yhtiöistä.